Indian pharmaceutical companies are set for a steady September quarter. Growth in the US generics market and domestic sales will drive performance. Companies like Apollo Hospitals, Lupin, and Aurobindo are expected to show strong results. Despite some cost pressures, the sector anticipates positive medium-term prospects. New product launches and expanding facilities will support earnings.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets